Glimiscore Mv2 Tab

Tablet

Type 2 diabetes mellitus in adults when diet and exercise alone are not enough; helps control post-meal and fasting blood glucose in patients requiring triple therapy.

Glimepiride increases insulin release from the pancreas and improves insulin sensitivity. Metformin reduces glucose production in the liver and improves peripheral glucose uptake. Voglibose slows carbohydrate digestion and absorption in the gut, reducing post-meal blood sugar spikes.

Oral tablet. Take exactly as prescribed, usually once daily with/after a main meal (often breakfast) to reduce stomach upset and risk of low sugar; swallow whole (do not crush/chew if modified-release). Monitor blood glucose regularly.

Hypoglycaemia, nausea, vomiting, diarrhoea, abdominal pain, flatulence, bloating, headache, dizziness

Risk of hypoglycaemia (higher with missed meals, alcohol, heavy exercise, elderly, kidney/liver disease); metformin may rarely cause lactic acidosis—seek urgent care for rapid breathing, severe weakness, abdominal pain, drowsiness. Avoid in severe renal impairment; use caution in liver disease, dehydration, severe infection, or before/after major surgery. Temporarily stop metformin around iodinated contrast procedures as advised by a doctor. Monitor kidney function, vitamin B12 with long-term use.

Alcohol (increases hypoglycaemia and lactic acidosis risk), insulin/other antidiabetics (additive hypoglycaemia), beta-blockers (mask hypoglycaemia), corticosteroids/thiazide diuretics (raise glucose), ACE inhibitors (may increase hypoglycaemia), quinolones (alter glucose), iodinated contrast media (renal risk with metformin), cimetidine (may increase metformin levels)

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Glycomet Trio 2 Tablet, Glimistar-MV2 Tablet, Zoryl MV 2 Tablet, Amaryl M 2 + Voglibose Tablet, Gemer MV 2 Tablet